Clinical trials: Drug Reactions
Cardiac Toxicity, Chemotherapeutic Agent Toxicity
Cardiac Magnetic Resonance Imaging in Patients With Non-Hodgkin Lymphoma or Hodgkin Lymphoma Receiving Doxorubicin
RATIONALE: Diagnostic procedures, such as cardiac magnetic resonance imaging, may help doctors detect early changes in the heart caused by chemotherapy.
- Conditions
- Cardiac Toxicity, Chemotherapeutic Agent Toxicity, Lymphoma
- Trial name
- NCT00577798
- Testing
- contrast-enhanced magnetic resonance imaging
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of Nebraska
Polypharmacy
The Adverse Drug Reaction (ADRe) Profile for Polypharmacy
Polypharmacy, the use of multiple or inappropriate medications, has the potential to harm older adults by causing cognitive impairment, falls, and hospitalisations.
- Trial name
- ADRe-p (NCT03955133)
- Testing
- Adverse Drug Reaction ADRe Profile for Polypharmacy
- Where
- United Kingdom
- Volunteers
- 19 people
- Sponsor
- Swansea University
Kidney Failure, Acute
Achieving Medication Safety During Acute Kidney Injury
The utilization of clinical decision support (CDS) is increasing among healthcare facilities which have implemented computerized physician order entry or electronic medical records.
- Trial name
- NCT01134900
- Testing
- Pharmacy Dashboard Review and Intervention
- Where
- United States
- Volunteers
- 540 people
- Sponsor
- Vanderbilt University
Breast Cancer, Heart Disease
STOP Heart Disease in Breast Cancer Survivors Trial
The purpose of this study is to to examine the effects of atorvastatin, a type of statin, on changes to the heart among women undergoing breast cancer treatment.
- Conditions
- Breast Cancer, Heart Disease, Cardiotoxicity, Myocardial Dysfunction
- Trial name
- STOP (NCT02674204)
- Testing
- Atorvastatin
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Cedars-Sinai Medical Center
Ototoxicity
SPI-1005 for Prevention and Treatment of Tobramycin Induced Ototoxicity
The primary objective of this study is to determine the safety and efficacy of SPI-1005 treatment in CF patients with active pulmonary exacerbation that are receiving an IV course of tobramycin, determined by comparing hearing…
- Trial name
- NCT02819856
- Testing
- SPI-1005 Ebselen 200mg Capsule x1, SPI-1005 Ebselen 200mg Capsule x2, SPI-1005 Ebselen 200mg Capsule x3
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Sound Pharmaceuticals, Incorporated
Kidney Transplant; Complications, Toxicity
Effect of Tacrolimus Formulation on Neurological Side Effects in Older Kidney Transplant Recipients
Previous studies have shown that elderly patients experience higher trough levels of tacrolimus and are more sensitive to the effects of medications, they experience higher occurrence and severity of such medication related…
- Conditions
- Kidney Transplant; Complications, Toxicity, Drug Toxicity, Neurotoxicity
- Trial name
- NCT03461445
- Testing
- Envarsus, IR Tacrolimus
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- University of California, Davis
Urologic Diseases, Antibacterial Drug Adverse Reaction
Audit-and-feedback to Improve Antimicrobial-prescribing Among Urologists
Antimicrobial resistance is one of today''s most urgent public health problems. An important strategy to slow the spread of antimicrobial resistance is the promotion of judicious antimicrobial use.
- Trial name
- NCT04196777
- Testing
- Audit-and-feedback
- Where
- 3 sites in United States
- Volunteers
- 525 people, healthy volunteers welcome
- Sponsor
- Iowa City Veterans Affairs Medical Center
Pain, Postoperative, Medication Adherence
Evaluation of an Interactive Opioid Risk Education Program (STOMP) for Parents
Millions of children and adolescents are prescribed opioid pain relievers each year, placing them at risk for serious adverse events and misuse in the home setting.
- Conditions
- Pain, Postoperative, Medication Adherence, Opioid Use, Knowledge, Attitudes, Practice
- Trial name
- STOMP (NCT03287622)
- Testing
- Educational Intervention, Nudge
- Where
- United States
- Volunteers
- 712 people
- Sponsor
- University of Michigan
Breast Cancer, Non-Hodgkin's Lymphoma
Trial of Mesna to Prevent Doxorubicin-induced Plasma Protein Oxidation and Tumor Necrosis Factor Alpha (TNF-α) Release
The purpose of this study is to determine whether the drug mesna is able to block a series of chemical changes that occur in the blood of patients who receive the chemotherapy medicine doxorubicin.
- Trial name
- NCT01205503
- Testing
- Mesna, Saline, Doxorubicin
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Mara Chambers
Adverse Drug Reaction
Educational Intervention in Pharmacovigilance for Hospital Health Professionals
Spontaneous reports by health professionals generate the signals in pharmacovigilance. However, the passive method has limitations and the most important of them are the underreporting and the poor quality of data, hindering the…
- Trial name
- EIPhv (NCT02134587)
- Testing
- Multifaceted educational intervention
- Where
- Brazil
- Volunteers
- 203 people
- Sponsor
- Universidade Estadual Paulista Júlio de Mesquita Filho
Medication-Induced Dyskinesia
Study to Assess the Safety, Tolerability and Preliminary Efficacy of NLX-112 Versus Placebo in L-dopa-induced Dyskinesia
This is a double-blind, randomized, placebo-controlled Phase 2a study evaluating the safety, tolerability, and preliminary efficacy of up to 2 mg/day (1 mg BID) of NLX-112 versus placebo in patients with moderate to severe L-DOPA…
- Trial name
- NCT05148884
- Testing
- NLX-112
- Where
- 5 sites in Sweden
- Volunteers
- 27 people
- Sponsor
- Neurolixis SAS
Ototoxicity, Unspecified Adult Solid Tumor
Alpha-Lipoic Acid in Preventing Hearing Loss in Cancer Patients Undergoing Treatment With Cisplatin
RATIONALE: Alpha-lipoic acid may prevent or lessen hearing loss caused by cisplatin. PURPOSE: This randomized clinical trial is studying the effectiveness of alpha-lipoic acid in preventing hearing loss in cancer patients…
- Trial name
- NCT00477607
- Testing
- alpha-lipoic acid, Audiology, laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 39 people
- Sponsor
- US Department of Veterans Affairs
Breast Cancer
Acute Exercise Cardioprotection From Doxorubicin
In rodents, a single bout of exercise prior to injection of a chemotherapy agent used to treat breast cancer prevents or attenuates a number of markers of cardiac injury.
- Trial name
- NCT02006979
- Testing
- exercise
- Where
- Canada
- Volunteers
- 27 people
- Sponsor
- University of British Columbia
Carcinoid Syndrome, Metastatic Nonfunctional Well Differentiated Neuroendocrine Neoplasm
AMT-PET in Monitoring Telotristat Etiprate Treatment in Participants With MetastaticNeuroendocrine Neoplasm
This pilot trial studies how well telotristat etiprate works in treating participants with well differentiated neuroendocrine neoplasm that has spread to other places in the body and monitored by carbon C 11…
- Trial name
- NCT03453489
- Testing
- Carbon C 11 Alpha-methyltryptophan, Laboratory Biomarker Analysis, Positron Emission Tomography
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Drug Induced Liver Injury
Acetaminophen Adduct Formation in Non-Drinkers Taking Therapeutic Doses of Acetaminophen for Ten Consecutive Days
Acetaminophen is commonly used to treat fever or pain. Your body clears acetaminophen by processing it in the liver. During the processing, some of the acetaminophen may bind to proteins in the liver.
- Trial name
- Non-Drinker (NCT00616018)
- Testing
- acetaminophen
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Kennon Heard
Graft vs Host Disease, Congenital Aniridia
Safety and Performance Study of the ARGOS-IO System in Patients Undergoing Boston Keratoprosthesis Implantation
The ARGOS-IO pressure sensor is intended to be implanted in the human eye in combination with Boston Keratoprosthesis (BKPro) surgery and to remain in place indefinitely.
- Conditions
- Graft vs Host Disease, Congenital Aniridia, Chemical Burns, Stevens-Johnson Syndrome
- Trial name
- NCT02945176
- Testing
- ARGOS-IO system
- Where
- 2 sites in Germany
- Volunteers
- 13 people
- Sponsor
- Implandata Ophthalmic Products GmbH
Hepatitis C, Chronic
An Observational Study of the Safety of Direct-acting Antivirals in Patients With Hepatitis C
The investigators will assess whether patients with the Hepatitis C virus (HCV) who are prescribed direct-acting antiviral (DAA) medications experience higher rates of adverse events than patients with HCV who are untreated.
- Trial name
- NCT03423641
- Testing
- Direct Acting Antivirals
- Volunteers
- 33,808 people
- Sponsor
- Kaiser Permanente
Hand-foot Syndrome
Study of Pyridoxine for Hand-Foot Syndrome
Although pyridoxine has been used empirically for the prevention of capecitabine associated hand-foot syndrome (HFS), its efficacy needs to be demonstrated in prospective controlled trials.
- Trial name
- NCT00446147
- Testing
- Pyridoxine
- Volunteers
- 389 people, healthy volunteers welcome
- Sponsor
- Asan Medical Center
Chemical Injuries, Unspecified Complication of Corneal Transplant
Use of Cross-linked Donor Corneas as Carriers for the Boston Keratoprosthesis
The purpose of the pilot study is to test the efficacy and safety of riboflavin/Ultraviolet A (UVA) cross-linked human donor corneas as carriers for the Boston Keratoprosthesis (Boston KPro) in patients with higher risk for…
- Conditions
- Chemical Injuries, Unspecified Complication of Corneal Transplant, Autoimmune Diseases, Ocular Cicatricial Pemphigoid
- Trial name
- NCT01582880
- Testing
- Riboflavin
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Joseph B. Ciolino, MD
Cardiotoxicity
Staccato Prochlorperazine Thorough QT/QTc
To assess the safety of Staccato Prochlorperazine on cardiac repolarization (QTc interval duration) at 2 dose levels compared to placebo in healthy volunteers.
- Trial name
- NCT00543062
- Testing
- Inhaled prochlorperazine 5 mg, Inhaled prochlorperazine 10 mg, Oral moxifloxacin
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Alexza Pharmaceuticals, Inc.